What clinical trials support canakinumab's efficacy in cvd?

What clinical trials support canakinumab's efficacy in CVD?

Canakinumab reduces recurrent cardiovascular events in patients with prior heart attack and elevated CRP levels. The CANTOS trial, a large-scale study, showed 15% relative risk reduction in the composite endpoint of nonfatal MI, nonfatal stroke, or cardiovascular death.

Why does this trial receive so much attention?

CANTOS demonstrated that targeting inflammation directly lowers cardiovascular risk beyond lipid-lowering methods. The 150 mg dose proved effective while the 50 mg and 300 mg doses showed weaker or inconsistent results.

What happened to canakinumab after CANTOS?

Canakinumab did not receive FDA approval for cardiovascular indications. The manufacturer shifted focus to its established use in rare inflammatory diseases. The trial's commercial failure stemmed from lack of reimbursement and perceived high cost relative to statins and antiplatelet agents.

When does the canakinumab patent expire?

The core patent covering canakinumab's molecule expires in 2025. The company may extend exclusivity through new formulations or pediatric exclusivity extensions.